D. S. Malley, R. A. Hamoudi, S. Kocialkowski, D. M. Pearson, V. P. Collins et al., A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts, Acta Neuropathologica, vol.137, issue.5, pp.651-61, 2011.
DOI : 10.1093/jb/mvi048

M. Bienkowski, A. S. Berghoff, C. Marosi, A. Wohrer, H. Heinzl et al., Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions, Clinical Neuropathology, vol.34, issue.09, pp.34-250, 2015.
DOI : 10.5414/NP300904
URL : http://europepmc.org/articles/pmc4542181?pdf=render

A. Widhalm, E. Wohrer, C. Knosp, J. A. Marosi, and . Hainfellner, Clinical Neuropathology practice news 1?2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma, Clin Neuropathol, pp.33-39, 2014.

P. Karayan?tapon, N. Rivet, M. Entz?werle, E. L. Legrain, G. Zalcman et al., Validation of the high?performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial, Oncotarget, vol.7, pp.61916-61929, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01358205

F. E. Harrell, J. , K. L. Lee, and D. B. Mark, MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, Statistics in Medicine, vol.15, issue.4, pp.15-361, 1996.
DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4

J. Wager, S. Honnorat, F. Saikali, M. Fina, D. Sanson et al., Comparative assessment of 5 methods (methylation?specific polymerase chain reaction, MethyLight, pyrosequencing, methylation?sensitive high?resolution melting, and immunohistochemistry) to analyze O6? methylguanine?DNA?methyltranferase in a series of 100 glioblastoma patients, Cancer, vol.118, pp.4201-4212, 2012.

J. Dunn, A. Baborie, F. Alam, K. Joyce, M. Moxham et al., Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy, British Journal of Cancer, vol.33, issue.1, pp.124-155, 2009.
DOI : 10.1097/nen.0b013e31815f65fb

. Weiler, Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma, PLoS One, vol.7, p.33449, 2012.

R. A. Heim, G. E. Lothe, and . Lind, MGMT promoter methylation in gliomas?assessment by pyrosequencing and quantitative methylation?specific PCR, J Transl Med, vol.10, p.36, 2012.

G. Reifenberger, B. Hentschel, J. Felsberg, G. Schackert, M. Simon et al., Predictive impact of MGMT promoter methylation in glioblastoma of the elderly, International Journal of Cancer, vol.28, issue.6, pp.1342-1350, 2012.
DOI : 10.1200/jco.2010.28.18_suppl.lba2001

. Stenning, Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial, Acta Neuropathol Commun, vol.2, p.68, 2014.

D. Shen, T. Liu, Q. Lin, X. Lu, Q. Wang et al., MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study, PLoS ONE, vol.23, issue.9, p.107558, 2014.
DOI : 10.1371/journal.pone.0107558.s001

F. Monteverde, A. Tonissi, C. Ghiglia, C. Fillini, M. Bernucci et al., MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens, Int J Biol Markers, vol.30, pp.208-224, 2015.

V. Quillien, A. Lavenu, M. Sanson, M. Legrain, P. Dubus et al., Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients, Journal of Neuro-Oncology, vol.124, issue.3, pp.487-96, 2014.
DOI : 10.1007/s00401-012-1016-2
URL : https://hal.archives-ouvertes.fr/hal-00935512

G. Brigliadori, F. Foca, M. Dall-'agata, C. Rengucci, E. Melegari et al., Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma, Journal of Neuro-Oncology, vol.124, issue.2, pp.333-342, 2016.
DOI : 10.1007/s00401-012-1016-2

. Ho, Prognosis of glioblastoma with faint MGMT methylation?specific PCR product, J Neurooncol, vol.122, pp.179-88, 2015.